Overview

Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite treatment according to GINA (2009) Step 4 therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Genentech, Inc.

Treatments:

Omalizumab